71 related articles for article (PubMed ID: 33390325)
1. A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Duska LR; Krasner CN; O'Malley DM; Hays JL; Modesitt SC; Mathews CA; Moore KN; Thaker PH; Miller A; Purdy C; Zamboni WC; Lucas AT; Supko JG; Schilder RJ
Gynecol Oncol; 2021 Mar; 160(3):688-695. PubMed ID: 33390325
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO; Quiroga D; Johnson C; Brufsky A; Chambers M; Bhattacharya S; Patterson M; Sardesai SD; Stover D; Lustberg M; Noonan AM; Cherian M; Bystry DM; Hill KL; Chen M; Phelps MA; Grever M; Stephens JA; Ramaswamy B; Carson WE; Wesolowski R
Ther Adv Med Oncol; 2023; 15():17588359231217976. PubMed ID: 38152697
[TBL] [Abstract][Full Text] [Related]
3. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes and Effectiveness of CRLX101 for Solid Tumors: A Systematic Review and Meta-analysis.
Shamaeizadeh N; Sadeghi E; Varshosaz J
Curr Med Chem; 2024 Feb; ():. PubMed ID: 38415437
[TBL] [Abstract][Full Text] [Related]
5. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Moore KN; Oza AM; Colombo N; Oaknin A; Scambia G; Lorusso D; Konecny GE; Banerjee S; Murphy CG; Tanyi JL; Hirte H; Konner JA; Lim PC; Prasad-Hayes M; Monk BJ; Pautier P; Wang J; Berkenblit A; Vergote I; Birrer MJ
Ann Oncol; 2021 Jun; 32(6):757-765. PubMed ID: 33667670
[TBL] [Abstract][Full Text] [Related]
6. Circadian clock protein CRY1 prevents paclitaxel‑induced senescence of bladder cancer cells by promoting p53 degradation.
Jia M; Su B; Mo L; Qiu W; Ying J; Lin P; Yang B; Li D; Wang D; Xu L; Li H; Zhou Z; Li X; Li J
Oncol Rep; 2021 Mar; 45(3):1033-1043. PubMed ID: 33650658
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy prior to fertility-sparing surgery in cervical tumors larger than 2 cm: a systematic review on fertility and oncologic outcomes.
Burbano J; Heredia F; Sanabria D; Ardila EG; Viveros-Carreño D; Rodriguez J
Int J Gynecol Cancer; 2021 Mar; 31(3):387-398. PubMed ID: 33649006
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer.
Sato Y; Fukuda N; Fujiwara YU; Wang X; Urasaki T; Ohmoto A; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
In Vivo; 2021; 35(2):1211-1215. PubMed ID: 33622923
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J; Hussain M; Gschwend JE; Albers P; Oudard S; Castellano D; Daneshmand S; Nishiyama H; Majchrowicz M; Degaonkar V; Shi Y; Mariathasan S; Grivas P; Drakaki A; O'Donnell PH; Rosenberg JE; Geynisman DM; Petrylak DP; Hoffman-Censits J; Bedke J; Kalebasty AR; Zakharia Y; van der Heijden MS; Sternberg CN; Davarpanah NN; Powles T;
Lancet Oncol; 2021 Apr; 22(4):525-537. PubMed ID: 33721560
[TBL] [Abstract][Full Text] [Related]
10. Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma.
Vanella V; Festino L; Vitale MG; Alfano B; Ascierto PA
Expert Opin Emerg Drugs; 2021 Jun; 26(2):79-92. PubMed ID: 33686894
[TBL] [Abstract][Full Text] [Related]
11. Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation.
Koyanagi M; Imai S; Iwamitsu Y; Matsumoto M; Saigo M; Moriya A; Ogihara T; Nakazato Y; Yonezawa A; Nakagawa S; Nakagawa T; Matsubara K
Neuropharmacology; 2021 May; 188():108514. PubMed ID: 33684416
[TBL] [Abstract][Full Text] [Related]
12. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
13. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Powles T; Atkins MB; Escudier B; Motzer RJ; Rini BI; Fong L; Joseph RW; Pal SK; Sznol M; Hainsworth J; Stadler WM; Hutson TE; Ravaud A; Bracarda S; Suarez C; Choueiri TK; Reeves J; Cohn A; Ding B; Leng N; Hashimoto K; Huseni M; Schiff C; McDermott DF
Eur Urol; 2021 May; 79(5):665-673. PubMed ID: 33678522
[TBL] [Abstract][Full Text] [Related]
14. N-acylethanolamine-hydrolysing acid amidase: A new potential target to treat paclitaxel-induced neuropathy.
Toma W; Caillaud M; Patel NH; Tran TH; Donvito G; Roberts J; Bagdas D; Jackson A; Lichtman A; Gewirtz DA; Makriyannis A; Malamas MS; Imad Damaj M
Eur J Pain; 2021 Jul; 25(6):1367-1380. PubMed ID: 33675555
[TBL] [Abstract][Full Text] [Related]
15. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
Molina GE; Zubiri L; Cohen JV; Durbin SM; Petrillo L; Allen IM; Murciano-Goroff YR; Dougan M; Thomas MF; Faje AT; Rengarajan M; Guidon AC; Chen ST; Okin D; Medoff BD; Nasrallah M; Kohler MJ; Schoenfeld SR; Karp Leaf RS; Sise ME; Neilan TG; Zlotoff DA; Farmer JR; Mooradian MJ; Bardia A; Mai M; Sullivan RJ; Semenov YR; Villani AC; Reynolds KL
Oncologist; 2021 Jun; 26(6):514-522. PubMed ID: 33655682
[TBL] [Abstract][Full Text] [Related]
16. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.
Morita A; Hosokawa S; Yamada K; Umeno T; Kano H; Kayatani H; Shiojiri M; Sakugawa M; Bessho A
Thorac Cancer; 2021 Apr; 12(8):1248-1251. PubMed ID: 33651475
[TBL] [Abstract][Full Text] [Related]
18. Achillea millefolium alleviates testicular damage in paclitaxel-intoxicated rats via attenuation of testicular oxido-inflammatory stress and apoptotic responses.
Okkay U; Ferah Okkay I; Cicek B; Aydin IC; Ertugrul MS; Bayram C; Senyayla S; Sezen S; Mendil AS; Guven L; Hacimuftuoglu A
Andrologia; 2021 Jun; 53(5):e14028. PubMed ID: 33650701
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer.
Yang XG; Li YY; Zhao DX; Cui W; Li H; Li XY; Li YX; Wang D
Oncol Rep; 2021 Mar; 45(3):1306-1314. PubMed ID: 33650669
[TBL] [Abstract][Full Text] [Related]
20. Perspectives and controversies regarding the use of natural products for the treatment of lung cancer.
Wen T; Song L; Hua S
Cancer Med; 2021 Apr; 10(7):2396-2422. PubMed ID: 33650320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
